Request an Appointment
More Ways to Schedule
Pay Your Bill
Find a Doctor
Trauma & Surgical Critical Care
Cancer Care Locations
Heart Care Locations
Research & Clinical Trials
Health Info A-Z
Classes & Events
Carolinas Health Magazine
Informacion de la salud de busqueda (en Espanol)
Pay Your Bill
Register for a Class
Carolinas Mobile App
Cabarrus College of Health Sciences
Carolinas College of Health Sciences
Center for Advanced Practice
Center for Faculty Excellence
Center for Life Support Education
Carolinas Simulation Center
Center for Prehospital Medicine
Mercy School of Nursing
School of Nurse Anesthesia
UNC School of Medicine Charlotte Campus
Research and Clinical Trials
To compare overall survival (OS) between study arms in subjects treated with AGS-003 in combination with standard treatment (combination arm) versus active control of standard treatment alone (control arm)
The purpose is to determine the safety, effectiveness and best dose to use when giving Nivolumab in combination with Sunitinib, Pazopanib, or Ipilimumab for the treatment of metastatic renal cell carcinoma.
The purpose of the study is to compare the clinical benefit, as measured by duration of overall survival, of BMS-936558 vs. Everolimus in subjects with advanced or metastatic clear-cell renal cell carcinoma who have received prior anti-angiogenic therapy.
The purpose of this study is to classify patients with renal tumors by histological categorization, surgicopathological stage, presence of metastases, age at diagnosis, tumor weight and loss of heterozygosity for chromosomes 1p and 16q, to thereby define eligibility for a series of therapeutic studies.
This phase III clinical trial is studying how well combination chemotherapy and surgery work in treating young patients with Wilms tumor.
To determine if DASL subclassification can identify a group of patients with advanced
melanoma who are significantly more likely to respond to high dose IL-2-based therapy
(Class 2) than the historical 16% response rate in an unselected patient population.
The purpose of this registry is to collect information on patients who are receiving treatment with Proleukin in an organized way, and to learn more about patient care during and after treatment.
Everolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth or by blocking blood flow to the tumor. This phase III trial is studying everolimus to see how well it works in treating patients with kidney cancer who have undergone surgery.
About Carolinas HealthCare System
Who We Are
Corporate Financial Information
Diversity and Inclusion
Pay Your Bill
Quality Report Card
Join Carolinas HealthCare System
Connect with Us
© 2013 Carolinas HealthCare System 800-821-1535 |